Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Further Reading from MarketBeat Media Abbott Laboratories' October Price Plunge Is a Signal to BuyWritten by Thomas Hughes. Published 10/17/2025. 
Key Points - Abbott Laboratories' Q3 results did not catalyze a rally but also did not provide a reason to sell.
- Margin is solid, growth is present, and the capital return outlook is reliable.
- Analyst and institutional trends suggest these influential market groups will buy ABT on the dip.
Abbott Laboratories' (NYSE: ABT) October price plunge looks like a buying opportunity, with analyst and institutional trends suggesting both groups have been accumulating the stock. MarketBeat data show growing analyst coverage, including newly initiated ratings appearing within days of the Q3 earnings release. Coverage is rising, sentiment has firmed over the prior two quarters, and price targets are moving higher. Ahead of the release, the consensus implied roughly a 10% upside—enough to reach a new all-time high—while the high-end range suggested another ~10% beyond that. What No One's Saying About Amazon's 30k Layoff
First they cut jobs at Meta... now 30,000 at Amazon – its largest layoff in history. What's happening inside these Mag 7 companies, particularly as the stocks continue to soar to all- time highs? The same former hedge fund manager who predicted the dot com crash, the housing crisis and the fall of Lehman is now stepping forward to explain what's really going on... and what you should be doing with your money Learn more. Institutional investors have been steady buyers of this healthcare stock throughout the year. MarketBeat's tracking shows institutions bought about $1.50 for every $1.00 sold over the past 12 months, and buying accelerated in the second half of the year—reaching roughly $3.25 bought for every $1.00 sold as of mid-October. That activity creates a solid support base: institutions now own about 75% of the outstanding shares, providing a tailwind visible in the charts. 
The ABT chart reflects a market in a long-term uptrend that is consolidating ahead of its next meaningful move. The monthly view shows the stock pulling back from recent peaks but remaining in rebound mode, forming a Bullish Flag Pattern after the October 2023 trend-line bounce and the price reversal confirmed earlier this year. Abbott's price action may continue to consolidate through year-end, but the setup points toward higher levels in 2026, supported by growth, earnings quality, and capital returns. A move to new highs would be significant, potentially translating into roughly a $30 gain, or about 30% from current levels. Abbott Laboratories Q3 Release Is No Reason to Sell This Stock Abbott's Q3 results came in slightly below analysts' consensus but do not warrant selling the stock. Revenue growth missed the consensus by a narrow 0.17% margin, yet revenue still rose 6.9% year over year and margins remained strong. Foreign exchange, which has been a headwind for many S&P 500 companies, turned into a tailwind for Abbott this quarter and positively impacted both revenue and earnings. Revenue strength was broad-based across U.S. and international markets, led by a 9.9% increase in international sales and growth across three main reporting segments. Diagnostics was the weak spot, down 7.8% organically—largely reflecting declines in COVID-19-related sales that are not core to Abbott's long-term business. Other segments performed better, with Medical Devices up 12.5% organically and Established Pharmaceuticals up 7.1%. Margin trends were favorable. The company widened its adjusted operating margin by 40 basis points, producing leveraged income growth. Operating earnings rose 10.6% and net income grew 7.5%; adjusted EPS was $1.30, in line with expectations and up roughly 7.5% year over year. The key takeaway: Abbott's diversified business model supports steady growth and healthy margins, underpinning its capital return plans. Abbott Laboratories' Dividend Is Reliable and Growing Abbott's dividend is reliable and is expected to increase at a high-single- to low-double-digit pace for the foreseeable future. The company is a Dividend King with more than 50 consecutive years of annual increases. It pays a payout ratio of about 45% of earnings and projects meaningful earnings growth ahead. Long-term consensus estimates call for Abbott to grow earnings at a low-double-digit pace over the next five years—ample to support further dividend increases without compromising investment in growth. Its diversified portfolio across diagnostics, medical devices, nutrition, and branded generics provides multiple revenue streams that help buffer the company against sector-specific slowdowns. With a strong balance sheet and consistent cash flow, Abbott is well-positioned to sustain both growth initiatives and rising shareholder returns.
| 
